A retrospective evaluation of benign prostatic hyperplasia treatment by transurethral vaporization using a 1470 nm laser.
This article aims to evaluate the safety and efficacy of a new diode laser at a wavelength of 1470 nm, in the surgical treatment of benign prostatic hyperplasia (BPH). BPH is very common. Laser surgeries, such as photoselective vaporization of the prostate (PVP), have gained interest over the past decade because of their satisfying clinical results and reduced morbidity. A total of 24 patients who underwent transurethral vaporization of the prostate with a new diode laser prototype at a wavelength of 1470 nm were included in this retrospective study. The baseline characteristics of patients and treatment outcomes were evaluated at 4 weeks after the operation with the International Prostate Symptoms Score (IPSS), duration of catheterization, and maximum urinary flow rate (Qmax). The mean age of patients was 69 ± 8.6 years. The mean time of operation and hospitalization were 97 ± 39 min and 5.3 ± 5.2 days, respectively. The mean duration of catheterization after surgery was 3.1 ± 2.7 days. No recatheterizations or secondary surgeries were required. IPSS and Qmax at 4 weeks postoperatively were significantly changed compared with the baseline (p<0.001). Transurethral vaporization of the prostate using a 1470 nm laser is effective to treat benign prostatic hyperplasia.